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Abstract 
Objectives 
To determine the discrimination characteristics of a new algorithm and two existing symptom 
scoring systems for identification of patients with suspected colorectal cancer. 
Design 
Derivation of algorithm by a case-control study and assessment of discrimination 
characteristics using receiver operating characteristics (ROC) curves. Three colorectal cancer 
scoring systems were investigated. The Bristol-Birmingham (BB) equation, which we derived 
from a large primary care dataset; the CAPER score, previously derived from a primary care 
case-control study and a symptom score derived from National Institute of Clinical 
Excellence (NICE) guidance for urgent referral of symptomatic patients. Their discrimination 
characteristics were investigated in two datasets: the BB derivation dataset and the CAPER 
score derivation dataset. The main analyses were ROC curves and the areas under them for all 
three algorithms in both datasets. 
Setting 
Electronic primary care databases  
Main outcome measures 
Diagnosis of colorectal cancer 
Results 
In the BB dataset, areas under the curve were: BB equation 0.83 (95% CI: 0.82 to 0.84); 
CAPER 0.79 (95% CI: 0.79 to 0.80); the NICE guidelines 0.65 (95% CI: 0.64 to 0.66). In the 
CAPER dataset, areas under the curve were: BB 0.92 (95% CI 0.91 to 0.94); CAPER 0.91 
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(95% CI 0.89 to 0.93); NICE guidelines 0.75 (95% CI 0.72 to 0.79). In subjects under 50 the 
discrimination characteristics of NICE referral guidelines were no better than chance. 
Conclusions 
Both multivariable symptom scoring systems performed significantly better than NICE 
referral guidelines.  
 4 
What this paper adds 
What is already known on this subject 
Despite the availability of screening, the majority of colorectal cancers will continue to be 
diagnosed after presentation with symptoms 
Selection of patients for further investigation depends on combining information from a 
number of symptoms and signs 
The existing symptom scoring systems (NICE guidance and the CAPER score) to help 
primary care physicians identify which patients should be referred for further 
investigation have not been evaluated.  
What this study adds 
Both the new Bristol-Birmingham equation and the CAPER score are markedly better at 
discriminating between patients with and without colorectal cancer than current NICE 
guidelines  
In patients aged under 50 years current NICE guidelines for urgent referral have no ability to 
discriminate between patients with and without colorectal cancer  
 5 
Introduction 
Colorectal cancer remains an important cause of death in the UK. Poorer survival rates in 
international comparisons may be influenced by later presentation.
1-3
 Delays in presentation to 
medical care and diagnosis are well recognised.
4
 Despite introduction of a national screening 
programme in the UK for those aged 60 to 69, the majority of cancers will continue to be 
diagnosed clinically because most cancers occur after this age, some decline screening, and 
screening does not detect all cancers.
5
 
Diagnosis of colorectal cancer is difficult because the condition is relatively uncommon in 
primary care and the symptoms are also features of more common, benign conditions. A 
typical full-time general practitioner will diagnose only one new case annually.
6
 Colonoscopy 
is the main diagnostic test for suspected colorectal cancer, but this is an uncomfortable 
procedure, requires referral and has a small rate of important complications.  
There are a number of different approaches to helping general practitioners select patients for 
further investigation. Single symptoms have a low specificity for colorectal cancer, but 
symptom pairs may have more useful test characteristics.
7-8
 The National Institute for Clinical 
Excellence (NICE) published national Referral Guidelines for Suspected Cancer in 2000, and 
updated these in 2005.
9
 These use an algorithm based on age and the presence of certain 
clinical features. However the guidelines concentrate on typical presentations of cancer; it has 
been argued that they may even delay diagnosis in patients with atypical presentations.
10
 
Although the guidelines do not recommend referral of patients with constipation or abdominal 
pain, these features are clearly associated with cancer.
5 10
 It is possible that current referral 
guidance will reinforce the finding that diagnostic delay is most common in patients who 
present with change of bowel habit.
11
  
The CAPER score is a risk scoring system using multiple presenting symptoms.
12
 It was 
derived from a primary care based case-control study in a single primary care trust.
13-14
 The 
cases were 349 colorectal cancers diagnosed in persons aged over 40 in Exeter between 1998 
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and 2002. Five age, sex and practice matched controls were obtained for each case. In the 
CAPER scoring system, some clinical features – abnormal rectal examination, severe anaemia 
or rectal bleeding – are on their own considered sufficiently high risk to warrant investigation. 
The CAPER score itself is intended for use with patients without these high-risk features, but 
who have multiple low-risk symptoms. The score seeks to identify those at higher risk from 
this low-risk pool. The weaknesses of the CAPER study were that it was undertaken in a 
single geographical area, used paper-based records and was relatively small.
12
 
This paper describes the derivation of the Bristol-Birmingham (BB) equation and compares 
its performance to the NICE referral guidelines and the CAPER score, using the two different 
datasets used to derive the BB equation and the CAPER score. 
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Materials and Methods 
Derivation of the BB equation: identification of cases, controls and variables 
The BB equation was derived from data provided by The Health Improvement Network 
(THIN), a national database of electronic primary care records.
15
 THIN includes all 
consultations, prescriptions, diagnoses and primary care investigations for all patients in 
participating practices. There are 2.2 million currently active patients in over 300 practices, 
distributed across all regions of the U.K.  
We have previously reported the derivation of risk estimates for colorectal cancer based on 
symptom pairs.
16
 The multivariable model described here is an extension of this. Cases were 
all patients aged 30 years or older with a diagnosis of colorectal cancer between January 2001 
and July 2006 (data before this was excluded as direct laboratory transfer of haemoglobin 
values began around 2000). Seven controls per case, matched for practice, sex and age were 
selected using a computerised random number sequence (seven being the standard number 
offered in THIN database studies). Where possible, controls were matched to the same age in 
years as cases (this was possible for 96.4%): the remainder were matched within one year, 
two years etc., up to a maximum of five years. Only cases and controls with at least two years 
of electronic records before the date of diagnosis of the case (the index date) were used. For a 
small number of very old cases in small practices, fewer than seven controls could be found. 
THIN staff performed these stages.  
Read codes for 24 clinical features of colorectal cancer were selected (list available from 
authors) and identified in the medical records. Only the two years before the index date were 
studied. A new prescription may be a proxy for a symptom, such as a laxative for 
constipation. Initially, symptoms and prescriptions for such symptoms were studied 
separately. Weight loss was calculated from the most recent and previous weights and divided 
into two categories: ≥10% weight loss and 5% to 10% weight loss. Most patients did not have 
two recorded weights, so were labelled unknown. There is a specific Read code for weight 
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loss – doctors had at times used it without recording an actual weight; it was studied 
separately. Anaemia was defined if the most recent record of haemoglobin was less than 
11g/dl in women and less than 12g/dl in men.  
Three risk markers (as opposed to diagnostic features) were also studied: diabetes, obesity and 
deprivation. For diabetes, patients were considered to be exposed if they had been diagnosed 
with diabetes at any time before the index date. Obesity was defined as a body mass index 
greater than 30kg/m
2
 within two years of the index date.  Each patient was allocated a 
deprivation quintile based on the Townsend score of their postcode. Irritable bowel syndrome 
is a potential misdiagnosis: we identified all patients with a record of this diagnosis at any 
time. 
Derivation of the BB equation: data analysis 
The initial analysis used univariable conditional logistic regression. Several variables were 
combined after initial analyses. As the odds ratios for diarrhoea, constipation and abdominal 
pain were similar to the odds ratios for the related prescription for these symptoms, the pairs 
of variables were combined. From now on when we use the terms diarrhoea, constipation or 
abdominal pain, we are referring to either the symptom or a new related prescription for the 
symptom. The odds ratios for weight loss without a recorded weight were similar to that for 
≥10% weight loss;  for a haemoglobin result >14g/dl similar to that for no haemoglobin 
result; for a MCV >85 fl similar to that for no MCV result. These categories were combined. 
Variables associated with colorectal cancer with a p-value ≤0.1 were entered into 
multivariable conditional logistic regression analyses. The model included the following 
variables: constipation, diarrhoea, change in bowel habit, flatulence, a diagnosis of irritable 
bowel syndrome, abdominal pain, rectal bleeding, haemoglobin concentration (in 1g/dl 
bands), microcytosis in two bands (mean cell volume <80 fl and 80-84.99 fl), weight loss 
(<5%, 5% to 9.9% and 10%), venous thrombosis or thromboembolism, diabetes and obesity. 
The first stage of the multivariable analysis included only symptoms in clinically related 
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groups: intestinal motility symptoms included constipation, diarrhoea, change in bowel habit 
and flatulence; pain symptoms included irritable bowel syndrome and abdominal pain; 
bleeding symptoms included rectal bleeding, anaemia and microcytosis; systemic symptoms 
included weight loss and thromboembolism; obesity symptoms included diabetes and obesity. 
The next stage included included all symptoms. Variables where the p-value was greater than 
0.05 at any stage, including the final model, were excluded, though these were checked by 
adding them individually to the final model, using likelihood ratio testing.   
Discrimination characteristics 
To investigate the discrimination characteristics of the BB equation, individuals in the test 
dataset were allocated a score equal to their multivariable odds ratio. Because patients with a 
positive faecal occult blood test, or an abnormal rectal examination, or an abdominal mass 
unquestionably qualify for further investigation they were allocated an arbitrary maximum 
score of 100 points in order to make them the highest priority for referral. In this way the 
score reflected relative priority for further investigation.  
The CAPER scores of participants in this study were derived from the presence or absence of 
six features of colorectal cancer – constipation (25 points), diarrhoea (10), loss of weight (20), 
abdominal pain or tenderness (15), and one laboratory finding - low haemoglobin (10-
11.9g/dl 30 points; 12-12.9g/dl 20 points). The CAPER system was derived for use in a 
population with only low-risk symptoms, with investigation suggested for scores of ≥35 
points.  Patients with abnormal rectal examination, severe anaemia (haemoglobin <10 g/dl) or 
rectal bleeding were considered to need referral, so were also allocated an arbitrary score of 
100 (Table 2). 
The NICE guidelines offer a binary choice: urgent referral or no urgent referral – on the basis 
of a series of categorical variables: age over 40 years, age over 60 years, sex, menopausal 
status, diarrhoea (looser stools or increasing stool frequency) of six weeks’ duration, rectal 
bleeding, abdominal mass, abnormal rectal examination and anaemia. Urgent referral is 
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recommended for patients aged over 60 years with increased stool frequency or with rectal 
bleeding for six weeks; aged over 40 years with increased stool frequency and rectal bleeding 
for six weeks; with an abdominal mass or abnormal rectal examination; iron deficiency 
anaemia (Hb <11mg/dl) in men; iron deficiency anaemia (Hb <10mg/dl) in postmenopausal 
women.  
In the main analysis (NICE 3) we interpreted NICE guidance as follows. The occurrence of 
two consultations with diarrhoea or change in bowel habit separated by more than 35 but less 
than 120 days was considered to indicate increased stool frequency for at least six weeks. 
Consultations separated by more than 120 days are likely to be separate episodes. A single 
consultation with rectal bleeding was taken to indicate rectal bleeding for at least six weeks. 
We again assigned a score of 100 points for abdominal mass, positive faecal occult blood or 
abnormal rectal examination for consistency. We assigned one point for the following 
features in which urgent investigation is advised: diarrhoea plus rectal bleeding and aged over 
40 years; rectal bleeding and aged over 60; diarrhoea and aged over 60; haemoglobin <11g/dl 
with microcytosis in a man; and haemoglobin <10g/dl with microcytosis in a postmenopausal 
woman (age>52 was taken as a proxy for being postmenopausal). The score thus rose with the 
number of qualifying symptoms (Table 2). In the CAPER dataset, the mean cell volume was 
not available, so the requirement for microcytosis was dropped; therefore a haemoglobin <10 
g/dl in a man was allocated one point.  
Two sensitivity analyses used different interpretations of the NICE guidelines. In NICE 1, a 
single consultation with diarrhoea or change in bowel habit was taken to indicate diarrhoea 
for six weeks. In NICE 2, two consultations separated by more than 35 but less than 120 days 
but not change in bowel habit, were taken to indicate diarrhoea for six weeks. 
The receiver operating characteristics of a prediction model are usually superior in the dataset 
from which it was derived. To avoid this “home advantage”, two datasets were used to assess 
the predictive power of the equations: the dataset used to derive the BB equation (described 
above) and the CAPER dataset. The CAPER dataset includes 349 colorectal cancer cases and 
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1744 age and sex matched controls.
8
  The mean age of cases was 71.9 years (range 40 to 96) 
and 50.1% of the dataset was male. The CAPER dataset was obtained by searching both paper 
and electronic primary care records for symptoms. In the CAPER dataset, weight loss was 
recorded as only present or absent; therefore this was taken to be equivalent to a >10% weight 
loss.  
Receiver operating characteristics (ROC) curves were constructed and the area under the 
curve was determined for the three prediction models in both datasets. The large size of the 
THIN dataset allowed us to undertake extensive sensitivity analyses. We repeated ROC 
curves for men and women, for each year of diagnosis of cancer from 2001 to 2007 and in ten 
year age bands. To determine whether allocating a “mandatory referral” score to abdominal 
masses, positive faecal occult bloods or abnormal rectal examinations affected the findings, 
we excluded cases and controls with these features and repeated the analysis. Because the 
CAPER score was derived from persons aged 40 and over we also repeated the analysis in 
persons aged over 40. 
Yield 
We estimated the yield of colorectal cancers using these systems by calculating the positive 
predictive values (PPVs) at selected points of the ROC curves, using Bayes’ theorem 
(posterior odds = prior odds×likelihood ratio).
17
 To compare the systems, we used the points 
on the three ROC curves with the same sensitivity. We derived the prior odds from national 
incidence rates for 2006, stratified by age and sex.
18
   
 
Results 
We identified 5,477 cases and 38,314 controls in a total of 317 practices. Their mean age was 
70.6 years (range 30 to 105) and 53.1% were male. Demographic details of subjects are 
shown in Table 1. 
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Derivation of the BB equation 
In the univariable analyses, positive faecal occult bloods (odds ratio 24.5, 95% CI 5.1 to 118), 
abnormal rectal examination (101, 13.3 to 765.2) and abdominal mass (35.0, 20.8 to 58.9) 
were strongly associated with a diagnosis of colorectal cancer. (Table 3) As these features 
warrant investigation per se they were dropped from further modelling. A family history of 
colorectal cancer was recorded in only seven cases and eight controls (odds ratio 6.13 95% CI 
2.22 to 16.9). 
 
Multivariable analysis was carried out using 13 variables, plus the deprivation quintile. In 
multivariable analyses none of flatulence, irritable bowel syndrome, diabetes, obesity, 
thromboembolism, or deprivation quintile was independently associated with cancer. The 
final model therefore included eight variables: constipation, diarrhoea, change in bowel habit, 
abdominal pain, haemoglobin concentration mean cell volume and weight loss (Table 4).  
Discrimination characteristics 1. In the BB dataset 
Table 2 summarises the way in which scores were derived from the three equations. In the 
THIN dataset the area under the curve for the BB equation was 0.83 (95% CI: 0.82 to 0.84) 
and for CAPER was 0.79 (95% CI: 0.79 to 0.80). The area under the curve for the NICE 3 
interpretation of the NICE guidelines was 0.65 (95% CI: 0.64 to 0.66) and was consistently 
superior to NICE 1 and NICE 2. (Figure 1) Excluding patients under 40 made little difference, 
and excluding those with abdominal mass, positive faecal occult blood and abnormal rectal 
examination only made modest differences. In all analyses, the BB equation and CAPER 
score remained superior to NICE.  
For the BB equation and NICE guidelines the areas under the curve were similar in men and 
women. The CAPER score performed slightly better in women than men. The BB and 
CAPER scores performed similarly at all ages. However no interpretation of the NICE 
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guidelines performed better than chance at ages under 50. NICE guidelines performed best at 
age 80 to 89 years.  
Discrimination characteristics 2. In the CAPER dataset 
In the CAPER dataset, the areas under the curve were BB 0.92 (95% CI 0.91 to 0.94); 
CAPER 0.91 (95% CI 0.89 to 0.93); NICE 1 0.76 (95% CI 0.73 to 0.80). (Table 5) In this 
dataset the area under the curve for NICE 1 was greater than for NICE 3. (Figure 2) 
Yield 
Using the more conservative estimate of discrimination characteristics derived from the THIN 
dataset, NICE 3 has a sensitivity of 0.327 and a specificity of 0.974, giving a positive 
likelihood ratio of 12.5 and a positive predictive value (yield) of 3.1% at age 70-74. A point 
on the CAPER and BB ROC curves for the same age was selected to have the same 
sensitivity.  These points had the following characteristics: CAPER – positive likelihood ratio 
13.4 and PPV 3.3%.; BB – positive likelihood ratio 14.7 and PPV 3.7%. (Table 6) 
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Discussion 
In both datasets the overall discrimination characteristics of the BB equation were 
consistently slightly better than those of the CAPER score and both were superior to any of 
the interpretations of current guidance. NICE guidelines performed no better than chance in 
subjects aged under 50. 
 
Weakness and strengths 
The performance of all methods of identifying colorectal cancer was better in the CAPER 
dataset than in the THIN dataset. The CAPER dataset has some probable advantages: cases 
were identified from the cancer registry and clinical features of colorectal cancer were 
identified from both paper and electronic records.
12
 The overall standardised incidence of 
cancer in THIN is consistent with cancer registry data, but there is some under-recording, 
probably as a result of misclassification of solid tumours. Standardised incidence ratios for 
colorectal cancer range from 0.69 to 0.84 between 2000 and 2006.
19
 Data linkage to cancer 
registry records could improve the recording of outcomes. 
We did not use the ‘free text’ comments in the THIN records.20 This will have meant some 
symptom recording was missed, though there is no reason to believe this would be more 
common in cases than controls.
12
  
 
Comparison with previous literature 
NICE guidelines may perform less well than the BB equation and CAPER because they 
include fewer predictor variables, some of which only apply at certain ages. This means that 
NICE guidelines perform well for the minority of colorectal cancers with typical features (the 
first part of the ROC curve), but less well for the majority of cases with low risk but not no-
risk symptoms.
21
 Variables absent from NICE guidelines include constipation, loss of weight 
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and abdominal pain. Diarrhoea, rectal bleeding and anaemia are part of CAPER and BB at all 
ages, though have an age-restriction within NICE. The BB equation includes two further 
variables, microcytosis and change in bowel habit and divides haemoglobin level and weight 
loss into subcategories. Change in bowel habit is an important predictor of colorectal cancer, 
and clearly doctors use this term differently to either diarrhoea or constipation. One criticism 
of NICE guidance is that only the minority of patients with colorectal cancer have a high risk 
symptom before diagnosis, with the majority experiencing constipation, diarrhoea or 
abdominal pain (or a combination of these).
5
 Thus, it is not surprising that NICE fails to 
identify such patients, and that survival from colorectal cancer has improved little since they 
were published.  
Other referral guidelines and symptom scoring systems might be investigated in a similar 
way. For example, the Selva score was derived from patients referred to secondary care for 
investigation and makes use of a consultation questionnaire to elicit symptoms.
22
 It has been 
reported to have an area under the curve of 0.76 in a population of patients referred for 
investigation of suspected colorectal cancer
23
 though it had a very poor performance in the 
one reported primary care study.
24
 
Primary care datasets are an invaluable resource for investigating the discrimination 
characteristics of referral guidelines and therefore of informing recommendations. 
Multivariable models to guide referral have much better discrimination characteristics than 
current NICE guidelines and so have the potential to significantly improve the selection of 
patients for further investigation of colorectal cancer symptoms. There is a strong case for a 
cohort analysis to derive a statistical model of cumulative incidence of colorectal cancer. 
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Table 1: Demographic details of cases and controls in the Bristol-Birmingham database 
Age band 
Number of cases Number of controls 
Male (%) Female (%) Total (%) Male (%) Female (%) Total (%) 
30-39 21 (0.4%) 29 (0.5%) 50 (0.9%) 147 (0.4%) 203 (0.5%) 350 (0.9%) 
40-49 104 (1.9%) 109 (2.0%) 213 (3.9%) 728 (1.9%) 763 (2.0%) 1,491 (3.9%) 
50-59 425 (7.8%) 317 (5.8%) 742 (13.5%) 2,975 (7.8%) 2,219 (5.8%) 5,194 (13.6%) 
60-69 761 (13.9%) 572 (10.4%) 1,333 (24.3%) 5,334 (13.9%) 4,002 (10.4%) 9,336 (24.4%) 
70-79 1,021 (18.6%) 787 (14.4%) 1,808 (33.0%) 7,160 (18.7%) 5,509 (14.4%) 12,669 (33.1%) 
80-89 519 (9.5%) 634 (11.6%) 1,153 (21.1%) 3,667 (9.6%) 4,449 (11.6%) 8,116 (21.2%) 
90+ 60 (1.1%) 118 (2.2%) 178 (3.2%) 350 (0.9%) 808 (2.1%) 1,158 (3.0%) 
Total 2,911 (53.1%) 2,566 (46.9%) 5,477 (100.0%) 20,361 (53.1%) 17,953 (46.9%) 38,314 (100.0%) 
Source: The Bristol-Birmingham database was extracted from the THIN database of electronic primary care records 
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Table 2: Coefficients for the BB equation, scores for CAPER and for three interpretations of NICE guidelines on urgent referral of patients with 
suspected colorectal cancer 
Predictor variable BB CAPER NICE 1 NICE 2 NICE 3 
Constipation 2.06 25 Not applicable Not applicable Not applicable 
Diarrhoea 2.38 
10 per episode maximum 
of 4 episodes 
1 if aged >40 with rectal bleeding.  
1 if aged >60.  
1 if two consultations 35 to 119 
days apart and aged >60.  
1 if two consultations 35 to 119 
days apart & aged >40 and rectal 
bleeding.  
1 if two consultations 35 to 119 
days apart and aged >60.  
1 if two consultations 35 to 119 
days apart & aged >40 and rectal 
bleeding. 
Change in bowel habit 13.83 Not applicable Not applicable Not applicable 
Prescription of antispasmodic  
or abdominal pain 
3.82 
15 per episode maximum 
of 3 episodes 
Not applicable Not applicable Not applicable 
Rectal bleeding 20.11 100 1 if aged >60 1 if aged >60 1 if aged >60 
Haemoglobin 13.0 – 13.9 mg/dl 1.33 Not applicable Not applicable Not applicable Not applicable 
Haemoglobin 12.0 – 12.9 mg/dl 1.63 20 Not applicable Not applicable Not applicable 
Haemoglobin 11.0 – 11.9 mg/dl 2.54 30 Not applicable Not applicable Not applicable 
Haemoglobin 10.0 – 10.9 mg/dl 5.18 30 1 with MCV <80 fl in a man* 
1 with MCV<80 fl in a woman  
>52 years* 
1 with MCV <80 fl in a man* 
1 with MCV<80 fl in a woman  
>52 years* 
1 with MCV <80 fl in a man* 
1 with MCV<80 fl in a woman  
>52 years* 
Haemoglobin 9.0 – 9.9 mg/dl 8.08 100 
Haemoglobin <9.0 mg/dl 15.94 100 
Mean Cell Volume 80 – 84.9 fl 2.71 Not applicable Not applicable Not applicable Not applicable 
Mean Cell Volume <80 fl 7.67 Not applicable See Hb See Hb See Hb 
Weight loss 10% (or recorded) 2.92 20 Not applicable Not applicable Not applicable 
Weight loss 5% - 9.9% 1.37 Not applicable Not applicable Not applicable Not applicable 
Not known 1.21 Not applicable Not applicable Not applicable Not applicable 
Faecal Occult Blood 100 100 100 100 100 
Abnormal Rectal Examination 100 100 100 100 100 
Abdominal Mass 100 100 100 100 100 
* MCV criterion not required in CAPER dataset 
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Table 3: Initial variables considered for inclusion in the Bristol-Birmingham predictive model and their frequency in cases and controls  
Risk Description 
Cases (N = 5,477) Controls (N = 38,314) Odds ratio (95%  
confidence interval) Number (%) with this risk Number (%) with this risk 
1 New episode of Constipation with or without prescription of a Laxative 684 (12.49%) 1,867 (4.87%) 2.92 (2.66 to 3.22) 
2 New prescription of a Laxative (without a record of Constipation) 793 (14.48%) 2,184 (5.70%) 2.92 (2.67 to 3.20) 
3 New episode of Diarrhoea with or without prescription of an Antimotility Drug 830 (15.15%) 1,764 (4.60%) 3.82 (3.49 to 4.18) 
4 New prescription for an Antimotility Drug (without a record of Diarrhoea) 158 (2.88%) 407 (1.06%) 2.80 (2.32 to 3.38) 
5 New episode of Change in Bowel Habit (with Diarrhoea/Antimotility Drug also mentioned) 137 (2.50%) 95 (0.25%) 10.25 (7.87 to 13.33) 
6 New episode of Change in Bowel Habit (with Constipation/Laxative also mentioned but no Diarrhoea) 134 (2.45%) 90 (0.23%) 10.85 (8.27 to 14.25) 
7 New episode of Change in Bowel Habit (without either Diarrhoea or Constipation mentioned) 344 (6.28%) 190 (0.50%) 13.90 (11.56 to 16.73) 
8 New diagnosis of Irritable Bowel Syndrome (with or without prescription of an Antispasmodic) 120 (2.19%) 303 (0.79%) 2.84 (2.29 to 3.52) 
9 New prescription for an Antispasmodic (without a record of Irritable Bowel Syndrome or Change in Bowel Habit) 500 (9.13%) 995 (2.60%) 3.78 (3.38 to 4.23) 
10 New episode of Rectal Bleeding or Melaena 853 (15.57%) 460 (1.20%) 16.17 (14.26 to 18.33) 
11 New episode of Faecal Occult Blood Present without mention of Rectal Bleeding or Melaena 7 (0.13%) 2 (0.01%) 24.50 (5.09 to 117.94) 
12 Weight Loss >10% within the past 2 years 183 (3.34%) 356 (0.93%) 3.72 (3.10 to 4.46) 
13 Weight Loss 5% to 10% within the past 2 years 245 (4.47%) 924 (2.41%) 1.91 (1.65 to 2.21) 
14 Weight Loss recorded within the past 2 years but actual weight not recorded or no weight loss 149 (2.72%) 286 (0.75%) 3.77 (3.08 to 4.61) 
15 New episode of Abdominal Pain or Tenderness 1,412 (25.78%) 2,660 (6.94%) 4.84 (4.50 to 5.22) 
16 New episode of Abnormal Rectal Examination 15 (0.27%) 2 (0.01%) 101.02 (13.34 to 765.19) 
17 New episode of Anaemia with a record of a low Haemoglobin 1,181 (21.56%) 1,030 (2.69%) 11.40 (10.33 to 12.58) 
18 New prescription of Iron for without a record of a low Haemoglobin 556 (10.15%) 1,424 (3.72%) 3.03 (2.72 to 3.36) 
19 New episode of flatulence 52 (0.95%) 116 (0.30%) 3.17 (2.28 to 4.40) 
20 Diabetes (ever diagnosed) 626 (11.43%) 3,679 (9.60%) 1.22 (1.11 to 1.34) 
21 Obesity (BMI >30) 600 (10.95%) 3,846 (10.04%) 1.11 (1.01 to 1.22) 
22 New diagnosis of Deep Venous Thrombosis or Pulmonary Embolism 24 (0.44%) 74 (0.19%) 2.27 (1.43 to 3.60) 
23 New episode of Abdominal mass 86 (1.57%) 19 (0.05%) 34.98 (20.78 to 58.86) 
24 Mean Cell Volume <80 fl 761 (13.89%) 284 (0.74%) 23.30 (20.04 to 27.09) 
Source: The Bristol-Birmingham database was extracted from the THIN database of electronic primary care records 
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Table 4: Results of multivariable conditional logistic regression analysis for the Bristol-Birmingham predictive model 
Factor Patients with this factor 
Cases Controls Univariable analysis Multivariate all significant factors 
Number and  
prevalence (%) 
Number and  
prevalence (%) 
Odds  
Ratio 
95% Confidence 
Interval 
Odds  
Ratio 
95% Confidence 
Interval 
 All patients 5,477  38,314      
1 Constipation 1,477 27.0% 4,051 10.6% 3.35 (3.12 to 3.60) 2.06 (1.88 to 2.26) 
2 Diarrhoea 988 18.0% 2,171 5.7% 3.75 (3.45 to 4.07) 2.38 (2.14 to 2.66) 
3 Change in Bowel Habit 615 11.2% 375 1.0% 13.11 (11.44 to 15.03) 13.83 (11.70 to 16.34) 
4 Flatulence 52 0.9% 116 0.3% 3.17 (2.28 to 4.40)   
5 Irritable Bowel Syndrome 135 2.5% 325 0.8% 2.99 (2.44 to 3.67)   
6 Abdominal pain / Antispasmodic 1,629 29.7% 3,121 8.1% 4.94 (4.60 to 5.30) 3.82 (3.49 to 4.18) 
7 Rectal bleeding 853 15.6% 460 1.2% 16.17 (14.26 to 18.33) 20.11 (17.35 to 23.32) 
8 Haemoglobin ≥14 g/dl or Not Known 2,963 54.1% 30,316 79.1% 1.00  1.00  
 Haemoglobin 13-13.999 g/dl 573 10.5% 3711 9.7% 2.02 (1.82 to 2.24) 1.33 (1.18 to 1.50) 
 Haemoglobin 12-12.999 g/dl 517 9.4% 2,484 6.5% 2.98 (2.66 to 3.33) 1.63 (1.42 to 1.87) 
 Haemoglobin 11-11.999 g/dl 417 7.6% 1,131 3.0% 5.38 (4.73 to 6.13) 2.54 (2.16 to 2.99) 
 Haemoglobin 10-10.999 g/dl 354 6.5% 417 1.1% 12.27 (10.47 to 14.39) 5.18 (4.19 to 6.39) 
 Haemoglobin 9-9.999 g/dl 268 4.9% 153 0.4% 23.49 (18.93 to 29.13) 8.08 (6.13 to 10.65) 
 Haemoglobin <9 385 7.0% 102 0.3% 50.88 (40.16 to 64.48) 15.94 (11.78 to 21.57) 
9 Mean Cell Volume ≥85 fl or Not Known 4,272 78.0% 37,168 97.0% 1.00  1.00  
 Mean Cell Volume 80-84.999 fl 444 8.1% 862 2.2% 4.95 (4.37 to 5.61) 2.71 (2.30 to 3.19) 
 Mean Cell Volume <80 fl 761 13.9% 284 0.7% 26.10 (22.42 to 30.39) 7.67 (6.23 to 9.44) 
10 No weight loss  752 13.7% 5,588 14.6% 1.00  1.00  
 Weight loss ≥10% or Recorded Weight Loss 351 6.4% 678 1.8% 3.84 (3.30 to 4.46) 2.92 (2.39 to 3.57) 
 Weight loss 5% to 10% 210 3.8% 852 2.2% 1.83 (1.55 to 2.17) 1.37 (1.09 to 1.73) 
 1 Recording / NK* 4164 76.0% 31,196 81.4% 0.96 (0.88 to 1.05) 1.21 (1.09 to 1.35) 
11 DVT or PE 24 0.4% 74 0.2% 2.27 (1.43 to 3.60)   
12 Diabetes 626 11.4% 3,679 9.6% 1.22 (1.11 to 1.34)   
13 Obesity 600 11.0% 3,846 10.0% 1.11 (1.01 to 1.22)   
* Patients with only one or fewer weight in whom it was not possible to calculate a percentage weight loss  
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Table 5: Areas under the curve in each age band and both sexes for a diagnosis of colorectal cancer using the BB (Bristol Birmingham) equation, the 
CAPER score and three algorithms based on NICE guidelines  
Tested in the THIN dataset 
Description of test dataset BB CAPER NICE 1 NICE 2 NICE 3 
Both sexes all ages 0.829 (0.822-0.835) 0.793 (0.786-0.800) 0.642 (0.633-0.651) 0.613 (0.604-0.622) 0.651 (0.642-0.659) 
Both sexes age 40 0.829 (0.823-0.836) 0.793 (0.786-0.801) 0.643 (0.634-0.652) 0.614 (0.605-0.623) 0.652 (0.643-0.661) 
Both sexes excluding “must refer“* 0.826 (0.819-0.833) 0.790 (0.782-0.797) 0.635 (0.626-0.644) 0.606 (0.597-0.615) 0.644 (0.635-0.653) 
Men 0.824 (0.815-0.833) 0.781 (0.771-0.791) 0.643 (0.631-0.655) 0.610 (0.597-0.622) 0.655 (0.642-0.667) 
Women 0.838 (0.829-0.848) 0.812 (0.802-0.822) 0.640 (0.627-0.653) 0.618 (0.604-0.631) 0.646 (0.633-0.659) 
30-39 years 0.758 (0.673-0.844) 0.762 (0.676-0.848) 0.520 (0.432-0.608) 0.520 (0.432-0.608) 0.520 (0.432-0.608) 
40-49 years 0.839 (0.805-0.873) 0.816 (0.779-0.853) 0.520 (0.477-0.563) 0.511 (0.469-0.553) 0.532 (0.489-0.575) 
50-59 years 0.818 (0.798-0.838) 0.796 (0.775-0.817) 0.540 (0.517-0.564) 0.537 (0.514-0.560) 0.567 (0.543-0.590) 
60-69 years 0.840 (0.827-0.854) 0.806 (0.791-0.821) 0.659 (0.641-0.677) 0.624 (0.606-0.642) 0.668 (0.650-0.686) 
70-79 years 0.828 (0.817-0.840) 0.791 (0.778-0.803) 0.665 (0.649-0.680) 0.631 (0.615-0.646) 0.670 (0.655-0.686) 
80-89 years 0.836 (0.822-0.850) 0.792 (0.776-0.808) 0.682 (0.663-0.701) 0.649 (0.630-0.669) 0.686 (0.666-0.705) 
90+ years 0.784 (0.746-0.822) 0.751 (0.712-0.791) 0.632 (0.583-0.681) 0.596 (0.547-0.645) 0.626 (0.576-0.675) 
Tested in the CAPER dataset 
Description of test dataset BB CAPER NICE 1 NICE 2 NICE 3 
Both sexes all ages 0.922 (0.905-0.938) 0.908 (0.890-0.927) 0.764 (0.732-0.797) 0.717 (0.681-0.752) 0.752 (0.718-0.786) 
* Cases and controls with a positive faecal occult blood test, an abdominal mass or an abnormal rectal examination are excluded from the THIN dataset for this analysis. 
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Table 6: Annual age specific incidence of colorectal cancer and positive predictive values if a patient meets the referral criteria (a positive test result) 
Equation Sensitivity 
Age band  50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 
Incidence per 100,000 39.1 69.8 110.6 171.3 247.2 316.0 375.4 369.7 
Likelihood Ratio Positive predictive value of a positive test result 
NICE 1 34.1% 5.7 0.2% 0.4% 0.6% 1.0% 1.4% 1.8% 2.1% 2.1% 
NICE 2 24.5% 13.3 0.5% 0.9% 1.5% 2.3% 3.3% 4.2% 5.0% 4.9% 
NICE 3 32.7% 12.5 0.5% 0.9% 1.4% 2.2% 3.1% 4.0% 4.7% 4.7% 
CAPER 32.6% 13.4 0.5% 0.9% 1.5% 2.3% 3.3% 4.2% 5.0% 5.0% 
BB 33.5% 14.7 0.6% 1.0% 1.6% 2.5% 3.7% 4.7% 5.6% 5.5% 
Source: Annual incidence for England in 2006 obtained from Northern and Yorkshire Cancer Registry and Information Service 
 
 Figure 1: Receiver operating characteristics curves for a diagnosis of colorectal cancer in the THIN 
dataset using the Bristol Birmingham equation, the CAPER score and three algorithms based on 
NICE guidelines  
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Figure 2: Receiver operating characteristics curves for a diagnosis of colorectal cancer in the 
CAPER dataset using the Bristol Birmingham equation, the CAPER score and three algorithms 
based on NICE guidelines  
 
 
 
